You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMolindone
Accession NumberDB01618
TypeSmall Molecule
GroupsApproved
DescriptionAn indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to moderate affinity for cholinergic and alpha-adrenergic receptors. Some electrophysiologic data from animals indicate that molindone has certain characteristics that resemble those of clozapine. (From AMA Drug Evaluations Annual, 1994, p283)
Structure
Thumb
Synonyms
(+-)-molindone
Moban
Molindona
Molindone
Molindonum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Molindone Hydrochloridetablet5 mg/1oralCore Pharma, Llc2015-09-15Not applicableUs
Molindone Hydrochloridetablet10 mg/1oralCore Pharma, Llc2015-09-15Not applicableUs
Molindone Hydrochloridetablet25 mg/1oralCore Pharma, Llc2015-09-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
MobanNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Molindone hydrochloride
ThumbNot applicableDBSALT001243
Categories
UNIIRT3Y3QMF8N
CAS number7416-34-4
WeightAverage: 276.374
Monoisotopic: 276.183778022
Chemical FormulaC16H24N2O2
InChI KeyInChIKey=KLPWJLBORRMFGK-UHFFFAOYSA-N
InChI
InChI=1S/C16H24N2O2/c1-3-13-11(2)17-14-5-4-12(16(19)15(13)14)10-18-6-8-20-9-7-18/h12,17H,3-10H2,1-2H3
IUPAC Name
3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-4,5,6,7-tetrahydro-1H-indol-4-one
SMILES
CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as indoles and derivatives. These are organic compounds containing an indole, which is a bicyclic ring system made up of a six-membered benzene ring fused to a five-membered nitrogen-containing pyrrole ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIndoles and derivatives
Sub ClassNot Available
Direct ParentIndoles and derivatives
Alternative Parents
Substituents
  • Indole or derivatives
  • Aryl alkyl ketone
  • Aryl ketone
  • Aralkylamine
  • Substituted pyrrole
  • Oxazinane
  • Morpholine
  • Heteroaromatic compound
  • Vinylogous amide
  • Pyrrole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Oxacycle
  • Azacycle
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationMolindone is used for the management of the manifestations of psychotic disorders.
PharmacodynamicsMolindone is a dihydroindolone compound which is not structurally related to the phenothiazines, the butyrophenones, or the thioxanthenes. Molindone has a pharmacological profile in laboratory animals which predominantly resembles that of major tranquilizers causing reduction of spontaneous locomotion and aggressiveness, suppression of a conditioned response and antagonism of the bizarre stereotyped behavior and hyperactivity induced by amphetamines. In addition, molindone antagonizes the depression caused by the tranquilizing agent tetrabenazine.
Mechanism of actionThe exact mechanism has not been established, however, based on electroencephalogram (EEG) studies, molindone is thought to act by occupying (antagonizing) dopamine (D2) receptor sites in the reticular limbic systems in the brain, thus decreasing dopamine activity. Decreased dopamine activity results in decreased physiological effects normally induced by excessive dopamine stimulation, such as those typically seen in manifestations of psychotic disorders.
Related Articles
AbsorptionRapidly absorbed from the gastrointestinal tract following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Most likely hepatic. 36 metabolites have been recognized, some of which may be active.

Route of eliminationHuman metabolic studies show molindone to be rapidly absorbed and metabolized when given orally. There are 36 recognized metabolites with less than 2-3% unmetabolized molindone being excreted in urine and feces.
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9637
Caco-2 permeable+0.6401
P-glycoprotein substrateSubstrate0.7994
P-glycoprotein inhibitor IInhibitor0.828
P-glycoprotein inhibitor IIInhibitor0.6826
Renal organic cation transporterInhibitor0.5863
CYP450 2C9 substrateNon-substrate0.8202
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.637
CYP450 1A2 substrateNon-inhibitor0.6779
CYP450 2C9 inhibitorNon-inhibitor0.939
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.7549
CYP450 3A4 inhibitorInhibitor0.7739
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7134
Ames testNon AMES toxic0.6399
CarcinogenicityNon-carcinogens0.9336
BiodegradationNot ready biodegradable0.9909
Rat acute toxicity2.9352 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5259
hERG inhibition (predictor II)Inhibitor0.5804
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg/1
Tabletoral25 mg/1
Tabletoral5 mg/1
Prices
Unit descriptionCostUnit
Moban 50 mg tablet5.12USD tablet
Moban 25 mg tablet3.02USD tablet
Moban 10 mg tablet2.57USD tablet
Moban 5 mg tablet1.79USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point180.5 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.474 mg/mLALOGPS
logP2.09ALOGPS
logP2.04ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)15.34ChemAxon
pKa (Strongest Basic)6.65ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area45.33 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity81.06 m3·mol-1ChemAxon
Polarizability32 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.41 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

DrugSyn.org

US3491093
General ReferencesNot Available
External Links
ATC CodesN05AE02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineMolindone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineMolindone may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Molindone is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Molindone.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Molindone.
adipiplonThe risk or severity of adverse effects can be increased when Molindone is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Molindone is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Molindone is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Molindone.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Molindone.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Molindone.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Molindone.
AmisulprideThe risk or severity of adverse effects can be increased when Molindone is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Molindone.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Molindone.
AmoxapineThe risk or severity of adverse effects can be increased when Molindone is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Molindone is combined with Amperozide.
AmphetamineMolindone may decrease the stimulatory activities of Amphetamine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Molindone.
ArticaineThe risk or severity of adverse effects can be increased when Molindone is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Molindone is combined with Asenapine.
AzaperoneThe risk or severity of adverse effects can be increased when Molindone is combined with Azaperone.
AzelastineMolindone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Molindone.
BaclofenThe risk or severity of adverse effects can be increased when Molindone is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Molindone.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Molindone.
BenzphetamineMolindone may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Molindone is combined with Benzyl alcohol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Molindone is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Molindone.
BrimonidineThe risk or severity of adverse effects can be increased when Molindone is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Molindone.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Molindone.
BrompheniramineThe risk or severity of adverse effects can be increased when Molindone is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Molindone is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Molindone.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Molindone.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Molindone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Molindone.
ButacaineThe risk or severity of adverse effects can be increased when Molindone is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Molindone is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Molindone is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Molindone.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Molindone.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Molindone.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Molindone.
CarbinoxamineThe risk or severity of adverse effects can be increased when Molindone is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Molindone.
CarisoprodolThe risk or severity of adverse effects can be increased when Molindone is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Molindone is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Molindone.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Molindone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Molindone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Molindone.
ChlorphenamineThe risk or severity of adverse effects can be increased when Molindone is combined with Chlorphenamine.
ChlorphentermineMolindone may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Molindone.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Molindone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Molindone is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Molindone.
CitalopramThe risk or severity of adverse effects can be increased when Molindone is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Molindone is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Molindone is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Molindone is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Molindone is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Molindone is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Molindone is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Molindone is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Molindone.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Molindone.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Molindone.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Molindone.
CyclizineThe risk or severity of adverse effects can be increased when Molindone is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Molindone.
CyproheptadineThe risk or severity of adverse effects can be increased when Molindone is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Molindone is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Molindone.
DapoxetineThe risk or severity of adverse effects can be increased when Molindone is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when Molindone is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Molindone.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Molindone.
DesloratadineThe risk or severity of adverse effects can be increased when Molindone is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Molindone.
DetomidineThe risk or severity of adverse effects can be increased when Molindone is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Molindone is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Molindone.
DextroamphetamineMolindone may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Molindone.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Molindone.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Molindone.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Molindone.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Molindone.
DifenoxinThe risk or severity of adverse effects can be increased when Molindone is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Molindone.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Molindone.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Molindone.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Molindone.
DimenhydrinateThe risk or severity of adverse effects can be increased when Molindone is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Molindone.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Molindone.
DoramectinThe risk or severity of adverse effects can be increased when Molindone is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Molindone.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Molindone.
DoxylamineThe risk or severity of adverse effects can be increased when Molindone is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Molindone is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Molindone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Molindone.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Molindone.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Molindone.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Molindone.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Molindone.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Molindone is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Molindone is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Molindone.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Molindone.
EntacaponeThe risk or severity of adverse effects can be increased when Molindone is combined with Entacapone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Molindone.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Molindone.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Molindone.
EscitalopramThe risk or severity of adverse effects can be increased when Molindone is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Molindone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Molindone.
EthanolMolindone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Molindone.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Molindone.
EthosuximideThe risk or severity of adverse effects can be increased when Molindone is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Molindone is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Molindone is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Molindone.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Molindone.
EtidocaineThe risk or severity of adverse effects can be increased when Molindone is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Molindone is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Molindone is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Molindone.
EtoperidoneThe risk or severity of adverse effects can be increased when Molindone is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Molindone.
EzogabineThe risk or severity of adverse effects can be increased when Molindone is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Molindone is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Molindone.
FenfluramineThe risk or severity of adverse effects can be increased when Molindone is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Molindone.
FexofenadineThe risk or severity of adverse effects can be increased when Molindone is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Molindone is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Molindone.
FlunarizineThe risk or severity of adverse effects can be increased when Molindone is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Molindone.
FluoxetineThe risk or severity of adverse effects can be increased when Molindone is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Molindone.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Molindone.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Molindone.
FluspirileneThe risk or severity of adverse effects can be increased when Molindone is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Molindone is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Molindone is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Molindone is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Molindone is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Molindone.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Molindone.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Molindone is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Molindone.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Molindone.
GuanfacineThe risk or severity of adverse effects can be increased when Molindone is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Molindone.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Molindone.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Molindone.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Molindone.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Molindone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Molindone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Molindone.
Hydroxyamphetamine hydrobromideMolindone may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Molindone.
HydroxyzineThe risk or severity of adverse effects can be increased when Molindone is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Molindone is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Molindone.
IndalpineThe risk or severity of adverse effects can be increased when Molindone is combined with Indalpine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Molindone.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Molindone.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Molindone.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Molindone.
KetobemidoneThe risk or severity of adverse effects can be increased when Molindone is combined with Ketobemidone.
LamotrigineThe risk or severity of adverse effects can be increased when Molindone is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Molindone is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Molindone.
LevocabastineThe risk or severity of adverse effects can be increased when Molindone is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Molindone is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Molindone is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Molindone.
LevomilnacipranThe risk or severity of adverse effects can be increased when Molindone is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Molindone.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Molindone.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Molindone.
LisdexamfetamineMolindone may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Molindone.
LithiumThe risk or severity of adverse effects can be increased when Molindone is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Molindone is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Molindone is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Molindone.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Molindone.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Molindone.
Lu AA21004The risk or severity of adverse effects can be increased when Molindone is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Molindone is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Molindone.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Molindone is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Molindone.
MeclizineThe risk or severity of adverse effects can be increased when Molindone is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Molindone is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Molindone.
MelperoneThe risk or severity of adverse effects can be increased when Molindone is combined with Melperone.
MephentermineMolindone may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Molindone.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Molindone.
MequitazineMolindone may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Molindone.
MetaxaloneThe risk or severity of adverse effects can be increased when Molindone is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Molindone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Molindone.
MethamphetamineMolindone may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Molindone is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Molindone is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Molindone is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Molindone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Molindone.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Molindone.
MethsuximideThe risk or severity of adverse effects can be increased when Molindone is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Molindone is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Molindone.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Molindone.
MetyrosineMolindone may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Molindone.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Molindone.
MilnacipranThe risk or severity of adverse effects can be increased when Molindone is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Molindone.
MirtazapineMolindone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Molindone.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Molindone.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Molindone.
NabiloneThe risk or severity of adverse effects can be increased when Molindone is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Molindone.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Molindone.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Molindone.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Molindone.
Nitrous oxideThe risk or severity of adverse effects can be increased when Molindone is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Molindone is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Molindone.
OlanzapineThe risk or severity of adverse effects can be increased when Molindone is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Molindone is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Molindone.
OpiumThe risk or severity of adverse effects can be increased when Molindone is combined with Opium.
OrphenadrineMolindone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Molindone.
OsanetantThe risk or severity of adverse effects can be increased when Molindone is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Molindone.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Molindone.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Molindone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Molindone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Molindone.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Molindone.
ParaldehydeMolindone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Molindone.
ParoxetineThe risk or severity of adverse effects can be increased when Molindone is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Molindone.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Molindone.
PerampanelThe risk or severity of adverse effects can be increased when Molindone is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Molindone is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Molindone.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Molindone.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Molindone.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Molindone.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Molindone is combined with Phenoxyethanol.
PhentermineMolindone may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Molindone is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Molindone.
PipamperoneThe risk or severity of adverse effects can be increased when Molindone is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Molindone is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Molindone is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Molindone is combined with Pomalidomide.
PramipexoleMolindone may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Molindone is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Molindone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Molindone.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Molindone.
PrimidoneThe risk or severity of adverse effects can be increased when Molindone is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Molindone.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Molindone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Molindone.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Molindone.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Molindone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Molindone.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Molindone.
PropoxycaineThe risk or severity of adverse effects can be increased when Molindone is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Molindone.
PSD502The risk or severity of adverse effects can be increased when Molindone is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Molindone.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Molindone.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Molindone.
RamelteonThe risk or severity of adverse effects can be increased when Molindone is combined with Ramelteon.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Molindone.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Molindone.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Molindone.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Molindone.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Molindone.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Molindone.
RomifidineThe risk or severity of adverse effects can be increased when Molindone is combined with Romifidine.
RopiniroleMolindone may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Molindone.
RotigotineMolindone may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Molindone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Molindone is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Molindone is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Molindone.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Molindone.
SertindoleThe risk or severity of adverse effects can be increased when Molindone is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Molindone is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Molindone.
Sodium oxybateThe risk or severity of adverse effects can be increased when Molindone is combined with Sodium oxybate.
StiripentolThe risk or severity of adverse effects can be increased when Molindone is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Molindone.
SulpirideThe risk or severity of adverse effects can be increased when Molindone is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Molindone.
SuvorexantThe risk or severity of adverse effects can be increased when Molindone is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Molindone.
TasimelteonThe risk or severity of adverse effects can be increased when Molindone is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Molindone.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Molindone.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Molindone.
TetracaineThe risk or severity of adverse effects can be increased when Molindone is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Molindone is combined with Tetrodotoxin.
ThalidomideMolindone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Molindone.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Molindone.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Molindone.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Molindone.
ThiothixeneThe risk or severity of adverse effects can be increased when Molindone is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Molindone is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Molindone is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Molindone is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Molindone is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Molindone is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Molindone.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Molindone is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Molindone.
TrazodoneThe risk or severity of adverse effects can be increased when Molindone is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Molindone.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Molindone.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Molindone.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Molindone.
TriprolidineThe risk or severity of adverse effects can be increased when Molindone is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Molindone.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Molindone.
VigabatrinThe risk or severity of adverse effects can be increased when Molindone is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Molindone is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Molindone is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Molindone is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Molindone.
ZiconotideThe risk or severity of adverse effects can be increased when Molindone is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Molindone is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Molindone.
ZolazepamThe risk or severity of adverse effects can be increased when Molindone is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Molindone.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Molindone.
ZonisamideThe risk or severity of adverse effects can be increased when Molindone is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Molindone.
ZotepineThe risk or severity of adverse effects can be increased when Molindone is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Molindone is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  2. Seeman P, Tallerico T: Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry. 1998 Mar;3(2):123-34. [PubMed:9577836 ]
  3. Lidow MS, Goldman-Rakic PS: Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs. J Pharmacol Exp Ther. 1997 Nov;283(2):939-46. [PubMed:9353417 ]
  4. Froimowitz M, Cody V: The incorporation of butyrophenones and related compounds into a pharmacophore for dopamine D2 antagonists. Drug Des Discov. 1997 Aug;15(2):63-81. [PubMed:9342550 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Nguyen TV, Juorio AV: Down-regulation of tryptamine binding sites following chronic molindone administration. A comparison with responses of dopamine and 5-hydroxytryptamine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1989 Oct;340(4):366-71. [PubMed:2586632 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Nguyen TV, Juorio AV: Down-regulation of tryptamine binding sites following chronic molindone administration. A comparison with responses of dopamine and 5-hydroxytryptamine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1989 Oct;340(4):366-71. [PubMed:2586632 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Neeper R, Richelson E, Nelson A: Neuroleptic binding to muscarinic M2 receptors of normal human heart in vitro and comparison with binding to M1 and dopamine D2 receptors of brain. Neuropharmacology. 1991 May;30(5):527-9. [PubMed:1678146 ]
Comments
comments powered by Disqus
Drug created on August 29, 2007 14:15 / Updated on August 17, 2016 12:23